141106-23-2

Basic information

• Product Name: 1-BENZOXEPIN-5(2H)-ONE, 8-BROMO-3,4-DIHYDRO-
• Synonyms: 1-BENZOXEPIN-5(2H)-ONE, 8-BROMO-3,4-DIHYDRO-;8-bromo-3,4-dihydrobenzo[b]oxepin-5(2H)-one;8-Bromo-3,4-dihydro-2H-benzo[b]oxepin-5-one;8-bromo-3,4-dihydro-2H-1-benzoxepin-5-one
• CAS NO: 141106-23-2
• Molecular Formula: C₁₀H₉BrO₂
• Molecular Weight: 241.083
• Mol File: 141106-23-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 349.0±41.0 °C(Predicted)
• Appearance: /
• Density: 1.528±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-BENZOXEPIN-5(2H)-ONE, 8-BROMO-3,4-DIHYDRO-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZOXEPIN-5(2H)-ONE, 8-BROMO-3,4-DIHYDRO-(141106-23-2)
• EPA Substance Registry System: 1-BENZOXEPIN-5(2H)-ONE, 8-BROMO-3,4-DIHYDRO-(141106-23-2)

Safety Data

• Hazardous Substances Data: 141106-23-2(Hazardous Substances Data)

Usage

Uses

8-Bromo-3,4-dihydrobenzo[b]oxepin-5(2H)-one is a useful research chemical.

Upstream product

• 1096893-57-0 methyl 4-(3-bromophenoxy)butanoate 
• 157245-84-6 ethyl 4-(3-bromophenoxy)butanoate 
• 591-20-8 3-Bromophenol 
• 170638-88-7 4-(3-bromophenoxy)butanoic acid 

Downstream Products

• 1016734-79-4 8-bromo-2,3,4,5-tetrahydrobenzo[b]oxepin-5-amine 
• 1282529-99-0 8-bromo-N-(2-chloro-5-(4-methylpiperazine-1-carbonyl)phenyl)-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamide 
• 1282529-98-9 3-(8-bromo-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamido)-4-chlorobenzoic acid 
• 1282529-97-8 methyl 3-(8-bromo-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamido)-4-chlorobenzoate 
• 1282529-96-7 methyl 3-(8-bromo-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamido)-4-chlorobenzoate 
• 1189811-67-3 8-(3-(aminomethyl)phenyl)-N-(2-chlorophenyl)-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamide 
• 1189816-09-8 8-bromo-N-(2-chloro-4-(4-methylpiperazine-1-carbonyl)phenyl)-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamide 
• 1189816-32-7 4-(8-bromo-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamido)-3-chlorobenzoic acid 
• 1189816-31-6 methyl 4-(8-bromo-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamido)-3-chlorobenzoate 
• 1346161-51-0 methyl 4-(8-bromo-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamido)-3-chlorobenzoate 
• 1189811-71-9 2-(3-(2-((2-chlorophenyl)(methyl)carbamoyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepin-8-yl)phenyl)acetic acid 
• 1365345-71-6 C₂₃H₂₀BrClN₂O₃S 
• 1346161-50-9 8-bromo-N-(2-chloro-5-(dimethylcarbamoyl)phenyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamide 
• 1189811-46-8 N₈-(2-aminoethyl)-N₂-(2-chlorophenyl)-N₂-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2,8-dicarboxamide 

Relevant articles and documents

BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their production and compounds of formula (I) for use in treating a disease responsive to the inhibition of Bruton's tyrosine.

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6- dihydrobenzo[f]imidazo[1,2- d ][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2- methylpropanamide (GDC-0032): A β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity

Dysfunctional signaling through the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway leads to uncontrolled tumor proliferation. In the course of the discovery of novel benzoxepin PI3K inhibitors, we observed a strong dependency of in vivo antitumor activity on the free-drug exposure. By lowering the intrinsic clearance, we derived a set of imidazobenzoxazepin compounds that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels. One of these compounds, GDC-0032 (11l), was progressed to clinical trials and is currently under phase I evaluation as a potential treatment for human malignancies.

TRICYCLIC HETEROCYCLIC COMPOUNDS

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.